YARDLEY, Pa., April 12, 2016 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, will present new cytokine profile data from the analyses of wound fluid and tissue biopsies taken from venous leg ulcers at the Spring 2016 Symposium on Advanced Wound Care, being held at the Georgia World Congress Center in Atlanta, Georgia from April 13 – 17.
The Company will feature a poster summarizing the findings from their InBalance Venous Ulcer prospective, randomized, controlled trial. The clinical outcomes demonstrated the efficacy of MIST Therapy when used in combination with a good wound care regimen of care. The study met its primary and secondary endpoints of statistically significant greater percent reduction in ulcer area and number of healed ulcers in those treated with MIST compared to those that received good wound care alone.1 The cytokine profiles of wound fluid and tissue samples taken from a subset in each treatment group indicate that there is an anti-inflammatory effect from MIST Therapy. More so, there is an elevation of growth factors that stimulate angiogenesis (new blood vessel growth), which is required for healing wounds.
During the event, Alliqua will also sponsor two symposia featuring its MIST Therapy® Systems, Biovance®, sorbion® and TheraBond® 3D products. The first symposium, titled "Comprehensive Approach to Treating Venous Leg Ulcers and Improving Patient Outcomes," will be hosted on Thursday, April 14, and focuses on the treatment of Venous Leg Ulcers highlighting the solutions provided by the Alliqua BioMedical portfolio of products in the control of exudate and bioburden, and promotion of healing. The second, titled “Using an Innovative Ultrasound Technology to Reduce Biofilm and Improve Clinical Outcomes” will be hosted on Friday, April 15 and focuses on a review of the ability of MIST Therapy to destroy biofilms and the extended wound protection from microbes made possible with the use of Alliqua’s wound dressings.
"The Company’s programming at the Spring 2016 Symposium on Advanced Wound Care meeting demonstrates our dedication to providing not only an increasing portfolio of novel wound care technologies, but also the requisite practitioner education on each technology’s features and benefits,” said Dr. Janice Smiell, Chief Medical Officer of Alliqua. “We are excited to have a faculty of respected clinicians who appreciate Alliqua’s focus on providing advanced wound care solutions to address the challenges presented in the treatment of chronic wounds, especially venous leg ulcers, which are particularly frustrating to both patients and their healthcare providers.”
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions, committed to restoring tissue and rebuilding lives. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds. Alliqua currently markets its line of dressings for wound care under the SilverSeal® and Hydress® brands, as well as the sorbion sachet® and sorbion sana® wound care products, and its TheraBond® 3D advanced dressing which incorporates the TheraBond® 3D Antimicrobial Barrier Systems technology. The Company's Mist Therapy® System uses painless, noncontact low-frequency ultrasound to stimulate cells below the wound bed to promote the healing process. Alliqua also markets the human biologic wound care product Biovance®.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility, allows Alliqua to custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries. The Company has locations in Yardley, PA, Langhorne, PA and Eden Prairie, MN.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company’s liquidity to pursue its complete business objectives; inadequate capital; the Company’s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company’s products; technical problems with the Company’s research and products; the Company’s ability to expand its business through strategic acquisitions; the Company’s ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our filings with the SEC, including our most recent Annual Report on Form 10-K filed with the SEC, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
1Gibbons GW, Orgill DP, Serena TE, et al. A Prospective, Randomized, Controlled Trial Comparing the Effects of Noncontact, Low-frequency Ultrasound to Standard Care in Healing Venous Leg Ulcers. Ostomy Wound Management. 2015; 61(1):16-29.
CONTACT: Investor Relations: Westwicke Partners on behalf of Alliqua BioMedical, Inc. Mike Piccinino, CFA +1-443-213-0500 AlliquaBioMedical@westwicke.com